Regulators rule no new patients for Lilly’s oncology drug
After Lartruvo failed to show efficacy in trials, the EMA and FDA advised that no new patients should take the drug in combination with chemotherapy.
After Lartruvo failed to show efficacy in trials, the EMA and FDA advised that no new patients should take the drug in combination with chemotherapy.
Dolomite’s high throughput, single cell encapsulation set-up aims to accelerate delivery of RNA vaccines.